Shuichi Nakatsuru

This inventor holds 33 USPTO granted patents and 17 published patent applications, plus 2 CIPO patents and 22 EPO patents, primarily in Cancer Diagnostics. Top assignee: Oncotherapy Science, Incorporated. Active years: 2009-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shuichi Nakatsuru. Retrieved from https://idiyas.com/inventor/shuichi-nakatsuru

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 17)

% Patents Active = 24.2

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 22 (Patent Applications = 64)

Average Co-Inventor Count = 3.4

ph-index = 7

Forward Citations = 126(Granted Patents)

Location History:

Saitama, JP (2009 - 2013)
Kawasaki, JP (2010 - 2014)
Kanagawa, JP (2010 - 2015)

Company Filing History:

33 out of 150

Oncotherapy Science, Incorporated

patents

Years Active: 2009-2015

Loading Chart...

Areas of Expertise:

Breast Cancer

Prostate Cancer

Monoclonal Antibodies

Peptide Vaccines

Tumor-targeting

Diagnostic Markers

Oncogenes

Gene Therapies

Cancer Treatments

Vaccine Development

Polypeptides

Epitope Peptides

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9187557 - Genes and polypeptides relating to breast cancers (2015-11-17),

2. 9139655 - Tumor-targeting monoclonal antibodies to FZD10 and uses thereof (2015-09-22),

3. 9120842 - SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same (2015-09-01),

4. 8795976 - Gene and polypeptide relating to breast cancer (2014-08-05),

5. 8771963 - Method of diagnosing esophageal cancer (2014-07-08),

6. 8709731 - DKK1 oncogene as therapeutic target for cancer and a diagnosing marker (2014-04-29),

7. 8685641 - Method of screening compounds for treating bladder cancer (2014-04-01),

8. 8673548 - Genes and polypeptides relating to breast cancers (2014-03-18),

9. 8663647 - Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides (2014-03-04),

10. 8614176 - Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides (2013-12-24),

11. 8470968 - SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same (2013-06-25),

12. 8354223 - Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3 (2013-01-15),

13. 8257711 - Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides (2012-09-04),

14. 8221751 - Tumor-targeting monoclonal antibodies to FZD10 and uses thereof (2012-07-17),

15. 8182997 - Prostate cancer related gene STYK1 (2012-05-22),

Title: Innovations in Cancer Research: The Patents of Shuichi Nakatsuru

Introduction: Shuichi Nakatsuru, based in Kawasaki, Japan, is a prominent figure in the field of cancer research, holding an impressive portfolio of 33 patents. His work primarily focuses on the identification and utilization of genes and polypeptides associated with breast cancer, paving the way for new diagnostic and therapeutic strategies.

Latest Patents: Among Nakatsuru's latest patents are innovative discoveries regarding human genes A7322 and F3374, which demonstrate heightened expression levels in breast cancer cases. These findings have significant implications for developing diagnostic tools and therapeutic agents targeting breast cancer. Additionally, Nakatsuru has contributed to the field with patents relating to tumor-targeting monoclonal antibodies to the FZD10 protein. His inventions encompass a variety of methods, including those for diagnosing and treating FZD10-associated diseases and in vivo imaging techniques for better patient management.

Career Highlights: Shuichi Nakatsuru has spent a considerable portion of his career at Oncotherapy Science, Incorporated, where he has leveraged his expertise to drive innovation in cancer therapeutics. His work is not only recognized for its scientific merit but also for its potential to impact the lives of patients battling cancer, showcasing his dedication to advancing medical science.

Collaborations: Nakatsuru has collaborated with esteemed colleagues such as Yusuke Nakamura, further enhancing the research and development endeavors within the realm of oncology. These partnerships have been instrumental in fostering a collaborative environment that encourages groundbreaking discoveries.

Conclusion: Shuichi Nakatsuru's contributions to cancer research, particularly through his patents on breast cancer biomarkers and treatment methods, illustrate his vital role in the ongoing fight against this disease. His relentless pursuit of innovation and collaboration within the scientific community continues to inspire developments that may one day lead to significant advancements in cancer diagnosis and therapy.

Profile summary based on public USPTO records.